The Impact of Early Achievement of Therapeutic Levels of Vancomycin in Critically ill Patients with Confirmed Gram-positive Infection: A Retrospective Cohort Study

Khalid Al Sulaiman (✉ alsulaimankh@hotmail.com)

King Abdulaziz Medical City

Abdulahman Alshaya

King Saud bin Abdulaziz University for Health Sciences

Amjad Alsaeed

King Saud bin Abdulaziz University for Health Sciences

Nadiyah Alshehri

King Abdulaziz Medical City

Ramesh Vishwakarma

King Abdullah International Medical Research Center

Hamdan Alzahrani

King Abdulaziz Medical City

Shmeylan Al Harbi

King Abdulaziz Medical City

Research Article

Keywords: Vancomycin, Trough level, Mortality, Infection, Critical care, Intensive care unit

Posted Date: August 31st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-384175/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Vancomycin is a commonly used antibiotic in critically ill patients for various indications. Critical illness imposes pharmacokinetic-pharmacodynamics challenges which makes optimizing vancomycin in this population cumbersome. Data are scarce on the clinical impact of time to therapeutic trough levels of vancomycin in critically ill patients. The aim of this study to evaluate the timing to achieve therapeutic trough level vancomycin on 30-day mortality in critically ill patients.

Method: A retrospective cohort study for all adult critically ill patients aged 18 years or older with confirmed Gram-positive infection and received vancomycin between January 1st, 2017 and December 31st, 2018 at a tertiary teaching hospital. We compared early (<48 hours) versus late (≥ 48 hours) attainment of vancomycin therapeutic trough levels. Primary outcome was the 30-day mortality in critically ill patients. Secondary outcomes were development of resistant organisms, eradicating microorganisms within 4-5 days of vancomycin initiation, vancomycin-induced acute kidney injury (AKI), and ICU length of stay (LOS).

Results: Two hundred and nine patients were included. No significant differences between comparative groups in baseline characteristics. Achieving therapeutic levels were associated with better survival at 30 days (OR: 0.48; 95% CI [0.26-0.87]; $p < 0.01$). Additionally, patients who achieved therapeutic levels of vancomycin early were less likely to develop resistant organisms (OR=0.08; 95% CI [0.01-0.59]; $p = 0.01$). The AKI and ICU LOS were not significant between the two groups.

Conclusion: Early attainment of vancomycin therapeutic levels was associated with possible survival benefit.

Background:

Infections may induce sepsis/septic shock, which is common in critically ill patients [1]. Mainly, Gram-positive infections are a growing concern given their resistant patterns, including methicillin-resistant *Staphylococcus aureus* (MRSA) with a reported mortality rate of up to 55% in critically ill patients [2, 3]. Vancomycin is still commonly used for suspected or confirmed Gram-positive infections in critically ill patients, despite having newer antimicrobial therapies with MRSA coverage [3–8]. The optimal dosing for vancomycin in critically ill patients is still unclear, despite being in the market for over 60 years [6, 7, 8].

Vancomycin requires a deep understanding of its pharmacokinetic-pharmacodynamic (Pk-PD) properties in various patient populations, and due to its narrow therapeutic index, vancomycin requires frequent therapeutic drug monitoring (TDM) to determine its safety and efficacy [4, 9]. Critically illness may significantly impact patients' volume of distribution, metabolism, and excretion, which adds another hurdle in promptly achieving therapeutic levels [9]. Several factors associated with failure to achieve initial therapeutic vancomycin trough levels in critically ill patients include male gender, young patients, not receiving loading dose, augmented renal clearance (ARC), and high albumin levels [3–5]. The recent recommendation suggested that the area under the curve (AUC)-guided vancomycin monitoring strategy

should be utilized in patients with MRSA infections due to superiority in efficacy as well as nephrotoxicity data [7, 8]. However, due to the complexity of AUC-guided vancomycin monitoring in clinical practice, the vancomycin trough level remains the most common and practical method for monitoring vancomycin efficacy and safety [8].

Vancomycin-induced acute kidney injury remains the most common adverse drug reaction (ADR) with the current TDM strategy that carries an increased risk of prolonged hospitalization [3, 4, 7, 8]. The fear of this ADR may cause some practitioners to be hesitant in dosing vancomycin, which may be predisposing patients to have more resistant organisms [3, 5]. Time to check therapeutic vancomycin trough levels was recommended to be drawn immediately before the fourth dose, which would be within two days per the previous TDM consensus from the American society of health-system pharmacists (ASHP), the infectious diseases society of America (IDSA), and the society of infectious diseases pharmacists (SIDP) [7, 8].

According to our knowledge, no study evaluates the timing to reach the therapeutic trough level in correlation with critically ill patients' clinical outcomes. Therefore, we aimed to study the correlation of early achievements of therapeutic trough levels of vancomycin on 30-day ICU mortality in critically ill patients.

Methods:

Study design

A retrospective, observational study of critically ill patients admitted to intensive care units (ICUs) with confirmed Gram-positive infections (e.g., MSSA, MRSA) and received intravenous vancomycin (weight-based dosing). All patients who met our inclusion criteria during the study period from 01/01/2017 to 31/12/2018 were included. Patients were divided into two groups based on the timing of achieving therapeutic vancomycin trough level during their ICU stay to an early and late group. We defined the early group as achieving therapeutic vancomycin trough levels within 48 hours of the first intravenous vancomycin exposure. The initial therapeutic trough target levels were determined according to infection types as 15–20 mg/L for severe infections (sepsis, pneumonia, meningitis, osteomyelitis, bacteremia, and endocarditis) and 10–15 mg/L for other infections. Vancomycin trough levels were obtained after reaching the steady state either 30 minutes before the fourth dose (without a loading dose) or 30 minutes before the third dose (with loading dose) in all patients included. Clinical pharmacy is a consulting service at KAMC. Critical care pharmacists are responsible for vancomycin TDM in their respected critical care units. No specific nomogram was followed.

Bacteria were identified in the blood, urine, wound, drainage, cerebrospinal fluid (CSF), and respiratory specimens. Gram stain is used to differentiate between Gram-positive and negative bacteria. Blood and MacConkey agar are used to culture microorganisms; after 24 hours of incubation, a single colony is selected and smeared directly as a thin film on a Matrix-assisted laser desorption/ionization-time of flight

(MALDI-TOF) biomerieux for pathogen identification, then VITEKR 2 is used thereafter to determine susceptibility.

Confirmed infection defined as sputum or endotracheal aspiration shows growth $\geq$ of 100,000 CFU/ml; bronchoalveolar lavage (BAL) shows growth $\geq$ of 10,000 CFU of single organism/ml for protected specimen brushes (PSBs), and $\geq$ 100,000 CFU of single organism/ml for BAL fluid. Additionally, urinary cultures were considered significant if showing a growth of $\geq$ 100,000 CFU/ml of no more than two species of microorganisms [30]. Cultures were excluded if the laboratory reported them as a "contaminant sample."

Eligibility criteria

Patients were enrolled in the study if they were critically ill, aged 18 years or older with confirmed Gram-positive infection, and received IV vancomycin between 01/01/2017 to 31/12/2018. Exclusion criteria include using vancomycin empirically without continued treatment (Duration <3 days) and no available vancomycin trough reading. Besides, patients with ICU LOS $\leq$ 1 day or > 60 days and/or labeled as "Do-Not-Resuscitate" status within the first 24 hours of ICU admission were excluded due to futility of care (Figure 1).

Setting

This study was conducted in the adult medical, surgical, trauma, and burn ICUs at KAMC, a tertiary-care academic referral hospital in Riyadh, Saudi Arabia. The ICU admits medical, surgical, trauma, burn patients and operates as closed units with 71 ICU beds capacity with 24/7 onsite coverage by critical care board-certified intensivists.

Data collection

Demographic data, Acute Physiology And Chronic Health Evaluation II (APACHE II) score, comorbidities, laboratory tests, cultures (Blood, Skin, Respiratory, Urine, CSF), microorganism (s), vancomycin date of administration, duration of vancomycin, vancomycin trough concentrations, time to reach the therapeutic levels, development of resistant organisms (e.g., Vancomycin Intermediate Staphylococcus Aureus (VISA), Vancomycin-Resistant Staphylococcus Aureus (VRSA) or Vancomycin-Resistant Enterococcus (VRE)), vancomycin induced acute kidney injury (VIN), the needs of dialysis, ICU mortality, ICU LOS were collected from an electronic record system (Best Care system). All variables have been compiled in an electronic data collection sheet. Patients were followed during ICU stay until death or discharge, whichever occurred first.

Endpoint (s)

The primary endpoint was to evaluate the association between timing of achieving therapeutic levels of vancomycin (early vs. late) in critically ill patients and mortality at 30 days from ICU admission. Secondary endpoints include developing a vancomycin-resistant organism, eradicating microorganisms within 4-5 days of vancomycin initiation, vancomycin-induced acute kidney injury (AKI), and ICU LOS.

Definition (s)/Procedure (s)

1. Susceptibility of Gram-positive bacteria based on Clinical Laboratory Standards Institute (CLSI) [11]:
 - Methicillin-Sensitive *Staphylococcus Aureus* (MSSA): Clinical isolate of *Staphylococcus aureus* sensitive to oxacillin; Minimal inhibitory concentration (MIC) < 2 µg/mL.
 - Methicillin-Resistant *Staphylococcus Aureus* (MRSA): Clinical isolate of *Staphylococcus aureus* resistant to oxacillin; Minimal inhibitory concentration (MIC) > 4 µg/mL.
 - Vancomycin Intermediate resistant *Staphylococcus aureus* (VISA): Clinical isolate of *Staphylococcus aureus* resistant to vancomycin; MIC 4-8 µg/mL.
 - Vancomycin-resistant *Staphylococcus aureus* (VRSA): Clinical isolate of *Staphylococcus aureus* that is resistant to vancomycin; MIC >8 µg/mL.
 - Vancomycin-Resistant Enterococcus (VRE): Clinical isolate of Enterococcus resistant to vancomycin; MIC >8 µg/mL.
 - Acute kidney injury (AKI) was defined using Acute Kidney Injury Network (AKIN) definition²⁹, which is a sudden decrease of renal function within 48 hours, defined by an increase in absolute SCr of at least 26.5 µmol/L (0.3 mg/dL) or by a percentage increase in SCr $\geq 50\%$ (1.5× baseline value) [10].

Data management and Statistical analysis

Data were entered in Microsoft Excel 2010. Categorical variables were reported using numbers and percentages. Continuous variables were reported using mean with standard deviation (SD) or median with interquartile range (IQR) when appropriate. We compared normally distributed numerical variables with the t-test and other continuous variables with the Mann-Whitney U test and categorical variables using the chi-square / Fisher exact test. The normality assumptions were assessed for all continuous variables using graphical representation (i.e., histograms and Q-Q plots) and statistical test (i.e., Shapiro-Wilk test). The baseline and clinical characteristics were compared between early and late initiation groups. No imputation was made for missing data as the cohort of patients in our study was not derived from random selection.

Multivariate logistic and generalized linear regression analyses were used to determine the relationship between therapeutic levels' timing and the different outcomes considered in this study. Variables that are clinically relevant were included in the model if they were different between study groups and associated with the primary outcome with a p-value of <0.2 and did not overlap with another variable. The odds

ratios (OR) estimates with the 95% confidence intervals (CI) were reported for the associations. We considered a P value of < 0.05 statistically significant and used SAS version 9.4 for all statistical analyses.

Sample size calculation

The sample size was calculated using Power Analysis and Sample Size (PASS) software (PASS 15 Power Analysis and Sample Size Software (2017)). From a pilot study of 30 patients, the ICU mortality was estimated to be 25% in the late group, and we were expecting a reduction in 30-day ICU mortality by 13.3% in the early group (i.e., 11.7%). With 80.003% power to detect a difference in ICU mortality between the two groups of 13.3 and one-sided Z-test statistics with pooled variance. A total sample size of 209 was considered to assess the study's primary endpoint.

Results:

Result Section

Of 209 patients included in this study, 99 (47.4%) patients' characteristics were included in the analysis of early achieving therapeutic levels of vancomycin compared to 110 (52.6%) patients included in late achievement.

Demographic and Clinical Characteristics

Characteristics of the patients are presented in Table 1. The mean age for patients was 65 years-old and 59 years-old in the early and late therapeutic levels attainment of vancomycin, respectively. In the study, 63 (63.6%) of the patients were males in early and 70 (63.6%) in the late achievement of vancomycin's therapeutic levels. More obese patients in the late group 24 out of 110 (21.8%) versus 13 out of 99 (13.1%); $p=0.157$. The median APACHE II score was 15 in both groups, $p=0.661$. Also, the median *modified sequential organ failure assessment (mSOFA)* score was 5 in early, compared with 6 in the late achievement, which was not statistically significant ($p=0.144$). Moreover, no major differences were observed between groups in their baseline characteristics (Table 1). More patients received vancomycin loading dose in the late group; 22.7% vs. 16.2%, respectively. However, this difference was not statistically significant ($p=0.233$).

Table 1

Baseline characteristics

	Early (N=99)	Late (N=110)	P-value
Age (years) ☒	65.21 (±16.88)	59.52(±20.29)	0.324*
Male ☒	63(63.6%)	70(63.6%)	>0.999**
Weight (kg) ☒	71.39 (±23.36)	68.45(±19.62)	0.324 **
Obese (body mass index > 30 kg/m2), ☒	13 (13.1%)	24 (21.8%)	0.157**
Admission category			
Medical ☒	69 (69.7%)	57 (51.8)	0.008
Surgical ☒	11 (11.1%)	19 (17.2%)	0.204
Trauma ☒	6 (6.06%)	14 (12.7%)	0.101
Burn ☒	4 (4.04%)	1 (0.90)	0.192^^^
Neuro ☒	8 (8.08%)	19 (17.2 %)	0.047
Others ☒	1(1.01%)	0 (0%)	0.473 ^^
Diabetes mellitus ☒	57(57.6%)	55 (50.0%)	0.273**
Hypertension ☒	66 (667%)	64(58.2%)	0.207**
Liver disease ☒	9 (9.1 %)	14 (12.7%)	0.402**
Chronic kidney disease ☒	13 (13.1%)	16 (14.5%)	0.768**
Heart failure ☒	17(17.2%)	17 (15.5%)	0.737**
Acute coronary syndrome ☒	24(24.2%)	23 (20.9%)	0.564**
mSOFA score, Δ	5 (3-7)	6 (4-8)	0.144***
APACHE II Score, Δ	15 (11-19)	15 (10-22)	0.661*
Admission GCS, ☒	9.30 (±4.63)	9.25 (4.77)	0.932*
Intubated on mechanical ventilation ☒	68 (49.3%)	70 (50.7%)	0.147**
Lactic acid (mmol/L), ☒	2.57(±2.24)	2.71(3.33)	0.757*
Serum creatinine (μmol/L), ☒	105.82(±71.34)	119.11(100.75)	0.280*
eGFR (ml/min/1.73 m2), ☒	80.35 (±44.66)	73.01 (41.76)	0.223*
Albumin (g/L), ☒	28.63 (±5.50)	31.46 (6.61)	0.002*
Platelets count (1000 × 10 ⁶ /L), ☒	296.82(±176.23)	251.18(141.32)	0.042*
Loading dose, *	16 (16.2%)	25(22.7%)	0.233**

Maintenance dose (mg/kg/day), $\bar{x}$	26.02 (± 11.7)	25.9 (± 11.7)	0.140**
* Data analyzed using independent samples t-test; ** Data analyzed using Chi-square *** Data analyzed using Mann–Whitney U test (Significant at $\alpha = 0.05$) ($\bar{x}$) Data presented as n, (%) ($\bar{x}$) Data presented as Mean, standard deviation (SD) (Δ) Data presented as Median, 25 th percentile (Q1) – 75 th percentile (Q3)			

Severity and sources of infection /Microorganism (s)

Among 209 patients admitted to ICU, the primary source of infection in our population was bacteremia, followed by pneumonia. The most common species detected were Staphylococcus Spp., followed by Enterococcus Spp. and Streptococcus Spp. respectively (Table 2).

Table 2

Severity/Source of infection and microorganism (s)

		Early (N=99)	Late (N=110)	P-value
Sources of gram-positive infection ☒	Bacteremia	63(63.6%)	69(62.7%)	0.891*
	1. MSSA Bacteremia	2 (3.1%)	7 (10.1%)	0.168**
	1. MRSA Bacteremia	11(17.4%)	13 (18.8%)	0.837*
	1. Others	50 (79.3%)	49 (71.0%)	0.268*
	Pneumonia	18(18.2%)	26(23.6%)	0.334*
	Skin/wound infection (s)	8(8.1%)	6(5.5%)	0.448**
	Other source of infection	10(10.1%)	9(8.2%)	0.629**
Organism ☒	Staphylococcus aureus	37(37.4%)	43(39.1%)	0.133*
	Staphylococcus (Non-aureus)	49(49.5%)	44(40.0%)	
	Streptococcus Spp	2(2.0%)	9(8.2%)	
	Enterococcus Spp	6(6.1%)	10(9.1%)	
	Others	5(5.1%)	4(3.6%)	
*Data analyzed using Chi-square				
**Data analyzed using Fischer exact				
(☒) Data presented as n, (%)				

Study outcome (s)

The descriptive and regression analysis of outcomes shows that patients who achieved therapeutic levels of vancomycin early have 18.2% ICU mortality within 30 days compared with 19.1% for those who achieve therapeutic levels after 48 hours (OR: 0.48 (0.26, 0.87); p-value = 0.0151) (Table 3).

Table 3

Regression analysis for the outcomes of vancomycin early achieving as compared with late achieving therapeutic level

Outcomes	Early (N=99)	Late (N=110)	P-value	Odds ratio (95%CI)	P-value
ICU mortality within 30 days ☒	18 (18.2%)	21 (19.1%)	0.866 ^{^*}	0.48 (0.26 , 0.87)	0.015 [*]
Developing of vancomycin resistance ☒	1 (1%)	2 (1.8%)	>0.999 ^{^**}	0.08 (0.01, 0.59)	0.013 [*]
Eradication of microorganism within 4-5 days of vancomycin initiation. ☒	51 (51.5%)	66 (60.6%)	0.189 ^{^*}	0.74 (0.46 , 1.22)	0.236 [*]
Vancomycin induced acute kidney injury (AKI) ☒	23 (23.2%)	24 (22.0%)	0.834 ^{^*}	0.60 (0.34 , 1.04)	0.068 [*]
Continuous Outcome				beta coefficient (Estimates) (95%CI)	
ICU length of stay Δ	17 (8.0, 31.0)	22 (9.5, 36.0)	0.150 [^]	0.28(-0.01, 0.57)	0.058 ^{**}
^{^**} Fisher exact test/ ^{^*} Chi-square test used to calculate p-value. [^] Mann-Whitney-U test was used to calculate p-value. [*] P-value was calculated using multivariate logistic regression after adjusting for patients mSOFA scores. ^{**} P-value was calculated using negative binomial regression after adjusting for patients mSOFA scores. (☒) Data presented as n, (%) (Δ) Data presented as Median, 25 th percentile (Q1) – 75 th percentile (Q3)					

Moreover, one patient (1%) developed a vancomycin-resistant organism in the early achievement group compared with two patients (1.8%) in late (Table 3). On the other hand, 23.2 % of the patients developed an acute kidney injury when achieving the therapeutic target level of vancomycin within 48 hours of initiation (Early group), compared with 22.0 % in the late group; however, it was not statistically significant.

Among 47 patients who developed acute kidney injury, eight patients (17%) required dialysis during ICU stay, of which six patients (12.7 %) in the early group required dialysis compared to 2 patients (4.26%) in the late group. The most common concomitant nephrotoxic intravenous medications were piperacillin/tazobactam followed by furosemide (Table 4). Ten patients on the early group developed an AKI with the combination of vancomycin and piperacillin/tazobactam compared to 13 patients in the late group.

Table 4

Concomitant use with other intravenous nephrotoxic medications

Medication (s)	Early (N=99)	Late (N=110)	P-value
Flucloxacillin	0 (0%)	4 (3.6%)	0.123
Amikacin	8 (8.0%)	4 (3.63%)	0.235
Gentamicin	9 (9.09%)	7 (6.36%)	0.603
Colistin	11(11.11 %)	8 (7.27%)	0.348
Piperacillin/tazobactam	43 (43.4%)	42 (38.1%)	0.440
Sulfamethoxazole/trimethoprim	4 (4.04%)	0 (0%)	0.048
Furosemide	36 (36.3%)	28 (25.4%)	0.087
Contrast	16 (16.1%)	14 (12.7%)	0.479
All data presented as n, (%)			

Discussion

Our results show that in a broad population of adult ICU patients treated with vancomycin, the early attainment of therapeutic drug levels within 48 hours was associated with a reduced risk of 30-day ICU mortality. Several studies have correlated optimizing pharmacokinetic-pharmacodynamics (PK-PD) with better clinical outcomes in infections due to *Staphylococcus aureus* treated with vancomycin. Compared to methicillin-susceptible *S. aureus* (MSSA), MRSA is independently associated with an increased risk of hospital mortality; thus, early attainment of MRSA therapeutic levels is crucial [2, 4, 6, 12].

Several studies have evaluated different nomograms or dosing strategies for vancomycin; however, limited data provided an insight into the correlation between time to achieve vancomycin therapeutic levels and significant clinical outcomes [12–16]. The median time to reach a therapeutic level for vancomycin in previously reported data was three days, which would be considered late in our study definition [13–16]. However, a prospective multicenter study that validated the vancomycin consensus guideline nomogram published in 2009 had a median time of two days [17]. Many strategies are suggested to achieve earlier trough levels using continuous vancomycin infusion [18–20]. The timing to achieve therapeutic trough levels for vancomycin earlier in our study was associated with lower 30-day ICU mortality when compared to the late group. Our reported mortality was different between groups with (18 (18.2%) vs. 21 (19.1%)); however, the early attainment of vancomycin therapeutic levels was associated with a statistically significant difference when plotting the regression analysis (OR: 0.48; 95% CI [0.26–0.87]; $p < 0.01$). We believe that this outcome is a good hypothesis-generating finding, as it makes sense to have better survival when treating infections appropriately in a timely fashion.

We observed a low incidence of vancomycin associated resistance patterns in the early group (one patient) than in the late group (two patients). This finding aligns with a few studies that reported an increased risk of developing resistance patterns of vancomycin with subtherapeutic vancomycin levels (< 10 mg/L) and inability to reach an appropriate minimum inhibitory concentration (MIC) to optimize PK-PD targets [21, 22]. A study by Hidayat et al and colleagues reported higher infection-related mortality in patients with MRSA infections with high MIC (24% vs. 10%) [23]. We cannot claim a clear correlation for this outcome due to our small numbers and the fact that we did not report pathogen-specific MICs in our study. However, we reported the resistance patterns documented by our microbiology lab based on the electronic medical records based on the CLSI criteria [10].

Higher rates of AKIs were reported in studies that applied the AKIN criteria for nephrotoxicity as it reached 35%-37% when using intermittent vancomycin infusions when compared to our study (21–25%) [24–26]. High vancomycin trough levels, among other factors such as concurrent nephrotoxic agents, concurrent vasopressor therapy, and/or undergone a procedure, are common risk factors for developing acute kidney injury (AKI) in critically ill patients (Table 4) [24–30]. A recent systematic review suggested higher risk of AKI with the co-administration of piperacillin/tazobactam, however in our data its use was similar between groups [31].

An important observation was the difference between groups population in terms of their admission categories. More medical patients were included in the early group compared to the late group. Additionally, this may explain the ability to achieve early therapeutic vancomycin levels despite a similar mean maintenance dose between groups. Recently, more data have discussed the prevalence of augmented renal clearance (ARC) in patients with trauma-surgical and/or neuro admission category, which may lead to the inability to reach earlier therapeutic levels of vancomycin [32–34].

Our study has several limitations that include the retrospective nature of this study and the sample size. Our patient population's heterogeneity (medical, surgical, burn, and trauma ICU patients) might have affected our outcomes. Additionally, we reported mortality for a small sample size study with many potential confounders; however, none of these variables was shown to impact our outcome based on our univariate regression analysis. Additionally, we were able to report nephrotoxic medication co-administration and contrast use. We acknowledge the revised consensus guidelines for vancomycin monitoring in MRSA infections to use individualized target area under the curve (AUC) over MIC, however many clinicians are still using the previous recommendation for targeting trough levels of 15–20 mg/L in day-to-day practice [7, 8]. Adopting AUC/MIC consensus guidelines in the developed countries may need more time and education [7]. Future studies are needed to confirm our findings.

Conclusion

Early attainment of vancomycin therapeutic levels may be associated with plausible survival benefits. More studies are needed to provide an insight into these correlations.

Abbreviations

ICUs: Intensive care units, AKI: Acute kidney injury, LOS: Length of stay, MRSA: Methicillin-resistant Staphylococcus aureus, Pk-PD: Pharmacokinetic-pharmacodynamic, TDM: therapeutic drug monitoring, AUC: Area under the curve, ADR: Adverse drug reaction, IDSA: Infectious diseases society of America.

Declarations

Acknowledgements

We want to thank Reema A. Alobaid and Yasmin K. Assifan for their data collection support from electronic sources.

Author contributions

KS contributed to the conception and design of the research; AS, AMS, NS, HZ, and SH contributed to the design of the research; AMS, NS and RK contributed to the acquisition and analysis of the data; KS, AS, AMS, NS, HZ, and SH contributed to the interpretation of the data; KS, AS, AMS, NS, HZ, RK and SH drafted the manuscript. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

Funding:

None.

Availability of data and material

The datasets used and/or analyzed during the current study are available from corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved on November 2020, by King Abdullah International Medical Research Center (KAIMRC)-Institutional Review Board (IRB), Riyadh, Saudi Arabia (Reference No: RC20/587/R). All methods were performed in accordance with relevant guidelines and regulations.

Participants' confidentiality was strictly observed throughout the study by using anonymous unique serial number for each subject and restricting data only to the investigators. KAIMRC-IRB committee waived the informed consent due to its retrospective nature.

Consent for publication

Not applicable.

Competing interests

No author has a conflict of interest in this study.

References

1. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. *Nat Rev Dis Primers*. 2016;2:16045. Published 2016 Jun 30. doi:10.1038/nrdp.2016.45
2. Mehta Y, Hegde A, Pande R, et al. Methicillin-resistant *Staphylococcus aureus* in Intensive Care Unit Setting of India: A Review of Clinical Burden, Patterns of Prevalence, Preventive Measures, and Future Strategies. *Indian J Crit Care Med*. 2020;24(1):55–62. doi:10.5005/jp-journals-10071-23337
3. Aleidan FAS, Alkhelaifi H, Alsenaid A, et al. Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case-control study [published online ahead of print, 2020 Sep 20]. *Expert Rev Anti Infect Ther*. 2020;1–6.
4. Alshehri N, Ahmed AE, Yenugadhati N, et al. Vancomycin in ICU patients with gram-positive infections: Initial trough levels and mortality. *Ther Clin Risk Manag*. 2020;16:979–987.
5. Ye Z, Li C, Zhai S. Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review. *PLoS One*. 2014;9(6):e99044. doi:10.1371/journal.pone.0099044
6. Chuma M, Makishima M, Imai T et al. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients. *Ther Drug Monit*. 2017;1. doi:10.1097/ftd.0000000000000459
7. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2009;66(1):82–98.
8. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis*. 2020;71(6):1361–1364.
9. Udy, Andrew A., Roberts, Jason A., De Waele, Jan J., Paterson, David L., and Lipman, Jeffrey (2012). What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. *International Journal of Antimicrobial Agents* 39 (6) 455–457. <https://doi.org/10.1016/j.ijantimicag.2012.02.010>

10. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care*. 2007;11(2):R31. doi:10.1186/cc5713
11. The Clinical and Laboratory Standards Institute (CLSI) M60 ED2:2020 edition. (Accessed 02/09/2021)
12. Hanberger H, Walther S, Leone M, et al. Increased mortality associated with methicillin-resistant *Staphylococcus aureus* (MRSA) infection in the intensive care unit: results from the EPIC II study. *Int J Antimicrob Agents*. 2011;38(4):331–335.
13. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in *Staphylococcus aureus* Bacteremia. *Clin Microbiol Rev*. 2012 Apr;25(2):362–86. doi: 10.1128/CMR.05022-11. PMID: 22491776; PMCID: PMC3346297
14. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. *J Clin Pharm Ther*. 2004;29(4):351–357.
15. Wysocki M, Thomas F, Wolff MA, Pean Y, Ravaud Y, Herman B. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. *J Antimicrob Chemother*. 1995;35(2):352–354.
16. Villanueva RD, Talledo O, Neely S, et al. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study. *J Trauma Acute Care Surg*. 2019;87(5):1164–1171.
17. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. *Pharmacotherapy*. 2011;31(5):441–448.
18. Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. *Am Surg*. 2013;79(11):1185–1190.
19. Tafelski S, Nachtigall I, Troeger U, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application. *J Infect Public Health*. 2015;8(4):355–363.
20. Saugel B, Nowack MCM, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. *J Crit Care*. 2013;28(1):9–13.
21. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2008;46(2):193–200.
22. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteremia treated with vancomycin. *Antimicrob Agents Chemother*. 2008;52(9):3315–3320.
23. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity: Efficacy and toxicity. *Arch Intern Med*. 2006;166(19):2138–2144.

24. Hays WB, Tillman E. Vancomycin-associated acute kidney injury in critically ill adolescent and young adult patients. *J Pharm Pract.* 2020;33(6):749–753.
25. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. *Antimicrob Agents Chemother.* 2011;55(7):3278–3283.
26. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant *Staphylococcus aureus* pneumonia. *Clin Ther.* 2007;29(6):1107–1115.
27. Hall RG 2nd, Hazlewood KA, Brouse SD, et al. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: a retrospective cohort study. *BMC Pharmacol Toxicol.* 2013;14(1):12.
28. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion: Continuous versus intermittent infusion. *Anesthesiology.* 2009;111(2):356–365.
29. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion: Continuous versus intermittent infusion. *Anesthesiology.* 2009;111(2):356–365.
30. Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: A retrospective multivariate regression analysis. *Crit Care Med.* 2014;42(12):2527–2536.
31. Ciarambino T, Giannico OV, Campanile A, Tirelli P, Para O, Signoriello G, Giordano M. Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review. *Intern Emerg Med.* 2020 Mar;15(2):327–331. doi: 10.1007/s11739-020-02287-2. Epub 2020 Feb 10. PMID: 32040830
32. Udy AA, Jarrett P, Lassig-Smith M, Stuart J, Starr T, Dunlop R, Deans R, Roberts JA, Senthuran S, Boots R, Bisht K, Bulmer AC, Lipman J. Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. *J Neurotrauma.* 2017 Jan 1;34(1):137–144. doi: 10.1089/neu.2015.4328. Epub 2016 Aug 16. PMID: 27302851.
33. Barletta, Jeffrey F. PharmD; Mangram, Alicia J. MD; Byrne, Marilyn RN, CCRN; Sucher, Joseph F. MD; Hollingworth, Alexandra K. MD; Ali-Osman, Francis R. MD; Shirah, Gina R. MD; Haley, Michael MD; Dzandu, James K. PhD Identifying augmented renal clearance in trauma patients, *Journal of Trauma and Acute Care Surgery*: April 2017 - Volume 82 - Issue 4 - p 665–671 doi: 10.1097/TA.0000000000001387
34. Atkinson AJ Jr. Augmented renal clearance. *Transl Clin Pharmacol.* 2018;26(3):111–114. doi:10.12793/tcp.2018.26.3.111

Figures

Figure 1

Flow diagram of inclusion/exclusion criteria, and for eligible patients who underwent analysis.